The attached table shows the novel drugs marketed in 2018.


Order No. | Trade name | Common name | Approval date | Mechanism | Indication | Company |
56 | Motegrity | prucalopride | 2018-12-14 | 5-HT4 receptor agonist | Chronic idiopathic constipation | J & J/Shire |
55 | Xospata | gilteritinib | 2018-11-28 | Axl/Flt3 inhibitor | r/r-AML | Astellas Pharma |
54 | Firdapse | amifampridine | 2018-11-28 | Potassium channel blocker | Lambert-Eaton myasthenic syndrome | Catalyst Pharmaceuticals |
53 | Vitrakvi | larotrectinib | 2018-11-26 | TRK inhibitor | Advanced solid tumors harboring an NTRK gene fusion | Loxo Oncology |
52 | Daurismo | glasdegib | 2018-11-21 | SMO receptor agonist | Acute leukemia | Pfizer |
51 | Gamifant | emapalumab | 2018-11-20 | INFγ mAb | Primary hemophagocytic lymphohistiocytosis | Novimmune sobi |
50 | Aemcolo | rifamycin | 2018-11-16 | Rifamycin | Travelers’ diarrhea | Cosmo Pharmaceuticals |
49 | Yupelri | Read More
Related News
InnoCare Announces FDA Approval of Clinical Trial for BCL2 Inhibitor Mesutoclax in AML and MDS
PharmaSources July 14, 2025
Becoming Contracted Authors of PharmaSources
PharmaSources.com February 26, 2024
A Review of Progress of Immunotherapy Drugs for Hodgkin’s Lymphoma
PharmaSources/Yefenghong July 3, 2019 You may like
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation! Subscribe
Note: You can unsubscribe from the alerts at any time. Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation! Subscribe
Note: You can unsubscribe from the alerts at any time. Most popular
Apeloa Pharmaceutical releases first ESG
PharmaSources
May 12, 2025
Basic Concepts and Latest Trends in Radiation Biology: Emerging Insights and Future Directions
Sadia Ajmal
Sep 18, 2025
Methodology Validation in Chinese Pharmacopoeia 2025: How to Report Accuracy and Precision
Xing Xing
Sep 12, 2025
Digitalization in Procurement: From AI Forecasting to Blockchain Traceability
Saher Haider
Sep 19, 2025
|









(All Rights Reserved)